| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5723606 | CUMBERLAND | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(4 years ago) | |
Vaprisol is owned by Cumberland.
Vaprisol contains Conivaptan Hydrochloride.
Vaprisol has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Vaprisol are:
- US5723606
Vaprisol was authorised for market use on 29 December, 2005.
Vaprisol is available in injectable;intravenous dosage forms.
Vaprisol can be used as method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with hypervolemic hyponatremia.
The generics of Vaprisol are possible to be released after 15 December, 2019.
Drugs and Companies using CONIVAPTAN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 2005
Treatment: Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with hypervolemic hyponatremia
Dosage: INJECTABLE;INTRAVENOUS
VAPRISOL family patents
